Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 11 2023 - 4:05PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology
company focused on the treatment and prevention of virus-associated
cancers that impact patients worldwide, today announced that Mark
Rothera, its President and Chief Executive Officer, and Dan
Chevallard, its Chief Operating Officer and Chief Financial
Officer, are scheduled to participate in a fireside chat at the RBC
Capital Markets Global Healthcare Conference on Wednesday, May 17,
2023, at 4:05 p.m. EDT.
A live webcast of the fireside chat will be
available on the Investors section of the Viracta website under
"Events and Webcasts" and archived for 90 days.
About Viracta Therapeutics,
Inc.
Viracta is a precision oncology company focused
on the treatment and prevention of virus-associated cancers that
impact patients worldwide. Viracta’s lead product candidate is an
all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed/refractory Epstein-Barr
virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
EBV+ recurrent or metastatic nasopharyngeal carcinoma and
other advanced EBV+ solid tumors. Viracta is also pursuing the
application of its “Kick and Kill” approach in other
virus-related cancers.
For additional information please visit
www.viracta.com.
Investor Relations Contact:Ashleigh BarretoHead
of Investor Relations & Corporate CommunicationsViracta
Therapeutics, Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Apr 2024 to May 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From May 2023 to May 2024